Gland Pharma (GLAND) Share Price Falls 2.86% to Rs 2,938.30
- September 10, 2026
- Posted by: Harsh Piplani
- Category: News
Gland Pharma Share Price fell to Rs 2,938.30 on 10 September 2026, down Rs 86.60 or 2.86% from the previous close of Rs 3,024.90. At the time of the update, the company’s market capitalisation stood at Rs 48,817.76 crore, keeping the stock in the Large Cap category. The move matters because Gland Pharma is part of the Healthcare sector and the Pharmaceuticals & Drugs industry, where valuation and profitability comparisons often shape market attention during sharp intraday declines.
For readers looking at Gland Pharma Share Price Today, the supplied data confirms the price move but does not identify a company-specific reason behind it. What the data does show is a session that started stronger and then weakened through the day. The stock opened at Rs 3,039.90, which also turned out to be the intraday high, and later slipped to a low of Rs 2,916.65 before trading near Rs 2,938.30. Turnover was Rs 3.55 crore at the time this article was prepared.
That pattern makes the stock relevant not only as a price-action story, but also as a valuation and sector-context story. The available numbers allow a factual read of how the business is priced, how its profitability compares with industry medians, and where it stands against major listed pharmaceutical peers.
Gland Pharma (GLAND) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 2,938.3 |
| Previous Close | Rs 3,024.9 |
| Today's Move | -Rs 86.60 (-2.86%) |
| Open | Rs 3,039.9 |
| High | Rs 3,039.9 |
| Low | Rs 2,916.65 |
| Turnover | Rs 3.55 crore |
| Market Capitalisation | Rs 48,817.76 crore |
| Market Cap Category | Large Cap |
Gland Pharma Share Price reflects a session in which sellers remained in control after the opening tick. The stock began above the previous close, but that early firmness did not hold. Because the opening price and the day’s high were both Rs 3,039.90, the session peak was set right at the start. From there, the stock moved lower to Rs 2,916.65 before recovering modestly from the low.
This intraday structure is useful because it distinguishes a sustained decline from a flat or range-bound session. The stock was not simply weaker at the margin; it moved from the day’s top toward a significantly lower intraday level. For a Large Cap pharmaceutical stock, a 2.86% decline is enough to attract attention even without an identified trigger in the supplied dataset.
Technical context also adds perspective. The RSI is 69.82. Meanwhile, the stock remains above its 50-day moving average of Rs 2,861.25 and well above its 200-day moving average of Rs 2,208.90. That does not remove near-term weakness, but it suggests the latest fall is happening while the stock is still trading above both referenced longer-term averages.
Gland Pharma (GLAND) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 48,817.76 crore |
| P/E Ratio | 44.21x |
| P/B Ratio | 4.69x |
| ROE | 10.56% |
| ROCE | 14.96% |
| EPS | Rs 68.43 |
| Book Value Per Share | Rs 644.34 |
| Dividend Yield | 0.66% |
On the fundamentals, the company trades at a P/E ratio of 44.21 and a P/B ratio of 4.69. Return ratios show ROE of 10.56% and ROCE of 14.96%. EPS stands at Rs 68.43, book value per share at Rs 644.34, and dividend yield at 0.66%.
These figures create a mixed but readable profile. The valuation multiples are not low in absolute terms, especially in the context of a stock that saw a notable intraday decline. At the same time, the business remains profitable and capital efficient enough to support market attention. ROCE is stronger than ROE, which may matter for investors comparing operating efficiency with shareholder return generation.
Gland Pharma Share Price therefore sits in an interesting zone: the stock is not presented by the supplied data as a deep-value candidate, yet it is also not positioned at the most expensive end of the broader pharmaceutical landscape. That makes industry benchmarking necessary before drawing a conclusion from today’s move alone.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 44.21x |
| Benchmark Median P/E | 32.79x |
| Benchmark Average P/E | 49.1x |
| Benchmark P/E Range | 3.4x to 706.55x |
| Company P/B Ratio | 4.69x |
| Benchmark Median P/B | 3x |
| Benchmark Average P/B | 4.44x |
| Company ROE | 10.56% |
| Benchmark Median ROE | 11.83% |
| Benchmark Average ROE | 11.27% |
| Company ROCE | 14.96% |
| Benchmark Median ROCE | 13.75% |
| Benchmark Average ROCE | 13.75% |
| Company Market Capitalisation | Rs 48,817.76 crore |
| Benchmark Median Market Cap | Rs 759.52 crore |
| Benchmark Average Market Cap | Rs 14,312.16 crore |
The sector snapshot covers 200 companies in the same industry, which gives the benchmark data reasonable breadth. On this basis, Gland Pharma’s P/E of 44.21 is above the median industry P/E of 32.79 but below the average of 49.1. That places the stock above the middle of the pack on earnings valuation, without putting it at the extreme end of the range.
On price-to-book, the company’s P/B of 4.69 is above the median of 3 and slightly above the average of 4.44. This suggests the stock is not especially cheap on balance-sheet valuation versus the industry set. Profitability tells a more mixed story. ROE of 10.56% is below both the median of 11.83% and the average of 11.27, while ROCE of 14.96% is above both the median and average of 13.75.
Size is another important point. With a market capitalisation of Rs 48,817.76 crore, the company is far larger than the industry median market cap of Rs 759.52 crore and also above the average of Rs 14,312.16 crore. So the stock combines above-average size with above-median valuation and mixed profitability relative to the benchmark set.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,51,338.9 | 37.06 | 5.18 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,54,068.03 | 86.06 | 14.25 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,88,767.06 | 86.01 | 20.9 | 26.76 | 19.27 |
| Zydus Lifesciences | ZYDUSLIFE | 1,14,712.94 | 24.95 | 4.18 | 19.69 | 21.39 |
| Cipla | CIPLA | 1,11,803.57 | 32.79 | 3.14 | 11.83 | 16 |
Against major peers, Gland Pharma appears smaller on market capitalisation than all five highlighted names: Sun Pharmaceutical Industries, Divi's Laboratories, Torrent Pharmaceuticals, Zydus Lifesciences and Cipla. Its P/E of 44.21 is above Sun Pharma, Zydus and Cipla, but below Divi's and Torrent. Its P/B of 4.69 is below Sun Pharma, Divi's and Torrent, but above Zydus and Cipla.
Return ratios are where the comparison becomes more challenging. ROE of 10.56% is below all five peer figures listed in the supplied set. ROCE of 14.96% is also below Sun Pharma, Divi's, Torrent, Zydus and slightly below Cipla. In simple terms, the peer table shows a stock trading at a mid-to-upper valuation position while delivering return metrics that trail several large comparable names.
That does not by itself explain the day’s fall, but it does explain why the stock may be judged carefully when price weakness appears. Gland Pharma Share Price is being assessed in a peer environment where some larger companies show either lower valuation, higher profitability, or both.
Why Investors Are Watching Gland Pharma
- The stock declined 2.86% to Rs 2,938.30 in the latest session.
- It opened at Rs 3,039.90, which also marked the day's high, before falling to Rs 2,916.65.
- RSI stands at 69.82, while price remains above the 50 DMA of Rs 2,861.25 and the 200 DMA of Rs 2,208.90.
- P/E of 44.21 and P/B of 4.69 sit above industry medians.
- ROE is below the industry median, while ROCE is above the industry median and average.
- Peer data shows valuation is not at the cheapest end relative to several large listed pharma names.
About Gland Pharma
Gland Pharma operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. Based on the supplied market data, it is a Large Cap listed company with a market capitalisation of Rs 48,817.76 crore. That makes it substantially larger than the typical company in the industry benchmark set, even though it remains smaller than the biggest peer names used in this comparison.
Track Gland Pharma Share Price on Univest
UseUnivest top decliners screener,Univest market blogsto review live stock data, top decliners and related market analysis.
On Univest, investors can track Gland Pharma Share Price live alongside intraday price action, moving-average levels, valuation ratios and broader sector context. That can be useful when a stock is seeing a notable intraday decline and market participants want a single factual view of price, fundamentals and peer positioning.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why is Gland Pharma Share Price falling today?
Ans. The stock is down 2.86% today, falling Rs 86.60 from Rs 3,024.90 to Rs 2,938.30. The supplied data confirms the decline, but it does not provide a company-specific catalyst for the move.
What is Gland Pharma Share Price Today?
Ans. At the time of the update, the stock was trading at Rs 2,938.30. During the session, it moved between Rs 3,039.90 and Rs 2,916.65. The previous close was Rs 3,024.9.
What are the key valuation ratios for Gland Pharma?
Ans. The supplied data shows a P/E ratio of 44.21 and a P/B ratio of 4.69. EPS is Rs 68.43 and book value per share is Rs 644.34. The relevant peer median P/E is 32.79x.
How does Gland Pharma compare with major pharma peers?
Ans. Its P/E is higher than Sun Pharma, Zydus and Cipla, but lower than Divi's and Torrent. Its ROE is below all five highlighted peers in the comparison table. Comparable listed companies include Sun Pharmaceutical Industries, Divi's Laboratories, Torrent Pharmaceuticals.
